US5849769A
(en)
*
|
1994-08-24 |
1998-12-15 |
Medivir Ab |
N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection
|
ES2289791T3
(es)
|
1997-08-22 |
2008-02-01 |
Astrazeneca Ab |
Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
|
UA60365C2
(uk)
*
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
EP2298311B1
(en)
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
AU779089B2
(en)
|
1999-04-15 |
2005-01-06 |
Bristol-Myers Squibb Holdings Ireland Unlimited Company |
Cyclic protein tyrosine kinase inhibitors
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
HN2000000051A
(es)
*
|
1999-05-19 |
2001-02-02 |
Pfizer Prod Inc |
Derivados heterociclicos utiles como agentes anticancerosos
|
US6555693B2
(en)
|
2000-03-16 |
2003-04-29 |
Genesoft, Inc. |
Charged compounds comprising a nucleic acid binding moiety and uses therefor
|
US7078536B2
(en)
|
2001-03-14 |
2006-07-18 |
Genesoft Pharmaceuticals, Inc. |
Charged compounds comprising a nucleic acid binding moiety and uses therefor
|
AU2001277285A1
(en)
|
2000-08-09 |
2002-02-18 |
Agouron Pharmaceuticals, Inc. |
Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
|
WO2002014305A2
(en)
|
2000-08-17 |
2002-02-21 |
Lumera Corporation |
Design and synthesis of advanced nlo materials for electro-optic applications
|
EP1309563B1
(en)
|
2000-08-18 |
2005-05-11 |
Agouron Pharmaceuticals, Inc. |
Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases
|
HU230302B1
(hu)
|
2000-10-20 |
2015-12-28 |
Eisai R&D Management Co., Ltd. |
Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
|
UA74221C2
(uk)
*
|
2000-11-28 |
2005-11-15 |
Пфайзер Продактс Інк. |
Солі ізотіазол-4-карбоксаміду та їх використання як антигіперпроліферативних агентів
|
PT1343782E
(pt)
|
2000-12-21 |
2009-06-29 |
Smithkline Beecham Corp |
Pirimidinoaminas como moduladores de angiogénese
|
EP2275446A3
(en)
|
2001-01-05 |
2012-08-15 |
Pfizer Inc. |
Antibodies to insulin-like growth factor I receptor
|
WO2002083863A2
(en)
|
2001-04-17 |
2002-10-24 |
Sepracor, Inc. |
Thiazole and other heterocyclic ligands and use thereof
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
HN2002000156A
(es)
|
2001-07-06 |
2003-11-27 |
Inc Agouron Pharmaceuticals |
Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
|
US7265134B2
(en)
|
2001-08-17 |
2007-09-04 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US20030143165A1
(en)
*
|
2002-01-25 |
2003-07-31 |
Allan Evans |
NSAID-containing topical formulations that demonstrate chemopreventive activity
|
AU2003209119A1
(en)
|
2002-02-11 |
2003-09-04 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
WO2003068228A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Aryl ureas with angiogenesis inhibiting activity
|
AU2003210969A1
(en)
*
|
2002-02-11 |
2003-09-04 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenesis inhibiting activity
|
CA2483084A1
(en)
|
2002-05-02 |
2003-11-13 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US6989451B2
(en)
*
|
2002-06-04 |
2006-01-24 |
Valeant Research & Development |
Heterocyclic compounds and uses thereof
|
WO2003105843A1
(en)
*
|
2002-06-13 |
2003-12-24 |
Kinetek Pharmaceuticals, Inc. |
Methods of using isothiazole derivatives to treat cancer or inflammation
|
WO2004002481A1
(en)
|
2002-06-27 |
2004-01-08 |
Novo Nordisk A/S |
Aryl carbonyl derivatives as therapeutic agents
|
EP1527071A1
(en)
*
|
2002-07-25 |
2005-05-04 |
Pfizer Products Inc. |
Isothiazole derivatives useful as anticancer agents
|
ATE425753T1
(de)
|
2002-08-02 |
2009-04-15 |
Genesoft Pharmaceuticals Inc |
Biaryl-verbindungen mit antiinfektiver wirkung
|
MXPA05001958A
(es)
*
|
2002-08-19 |
2005-04-28 |
Pfizer Prod Inc |
Terapia de combinacion para enfermedades hiperproliferativas.
|
CA2503119A1
(en)
|
2002-10-25 |
2004-05-13 |
Genesoft Pharmaceuticals, Inc. |
Anti-infective biaryl compounds
|
US7129214B2
(en)
|
2002-12-10 |
2006-10-31 |
Oscient Pharmaceuticals Corporation |
Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif
|
EA008501B1
(ru)
|
2002-12-19 |
2007-06-29 |
Пфайзер Инк. |
2-(1н-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний
|
WO2004067530A1
(en)
*
|
2003-01-27 |
2004-08-12 |
Pfizer Products Inc. |
Isothiazole derivatives
|
UY28213A1
(es)
|
2003-02-28 |
2004-09-30 |
Bayer Pharmaceuticals Corp |
Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
|
DK1622569T3
(en)
|
2003-04-24 |
2015-12-14 |
Incyte Holdings Corp |
AZA-SPIRO-alkane derivatives as inhibitors of metalloproteases
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
RS53476B
(en)
|
2003-07-18 |
2014-12-31 |
Amgen Fremont Inc. |
Hepatocyte Growth Factor Binders
|
ME00294B
(me)
|
2003-07-23 |
2011-05-10 |
Bayer Pharmaceuticals Corp |
Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
CN101337930B
(zh)
|
2003-11-11 |
2010-09-08 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
BRPI0506662B8
(pt)
|
2004-01-06 |
2021-05-25 |
Novo Nordisk As |
compostos ativadores de glucoquinase
|
ES2246687B2
(es)
*
|
2004-02-11 |
2006-11-16 |
Miguel Muñoz Saez |
Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
|
WO2005081997A2
(en)
*
|
2004-02-20 |
2005-09-09 |
The Scripps Research Institute |
Isothiazole based protein kinase inhibitors
|
WO2005102327A1
(en)
*
|
2004-04-20 |
2005-11-03 |
Pfizer Products Inc. |
Dosage forms and methods of treatment using vegfr inhibitors
|
CA2564325A1
(en)
|
2004-04-30 |
2005-11-24 |
Bayer Pharmaceuticals Corporation |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
TW200538104A
(en)
*
|
2004-05-17 |
2005-12-01 |
Pfizer Prod Inc |
Phenyl derivatives for the treatment of abnormal cell growth
|
KR100859891B1
(ko)
|
2004-08-26 |
2008-09-23 |
화이자 인코포레이티드 |
단백질 키나제 억제제로서 거울상이성질체적으로 순수한아미노헤테로아릴 화합물
|
MX2007002246A
(es)
*
|
2004-08-26 |
2007-04-20 |
Pfizer Prod Inc |
Procedimientos para la preparacion de derivados de isotiazol.
|
WO2006030947A1
(ja)
|
2004-09-13 |
2006-03-23 |
Eisai R & D Management Co., Ltd. |
スルホンアミド含有化合物の血管新生阻害物質との併用
|
US8772269B2
(en)
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
ATE428421T1
(de)
|
2004-09-17 |
2009-05-15 |
Eisai R&D Man Co Ltd |
Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
|
EP1827434B1
(en)
|
2004-11-30 |
2014-01-15 |
Amgen Inc. |
Quinolines and quinazoline analogs and their use as medicaments for treating cancer
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
DE602006016085D1
(de)
|
2005-03-16 |
2010-09-23 |
Genentech Inc |
Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
|
US20060216288A1
(en)
*
|
2005-03-22 |
2006-09-28 |
Amgen Inc |
Combinations for the treatment of cancer
|
RU2413735C2
(ru)
|
2005-03-31 |
2011-03-10 |
Эдженсис, Инк. |
Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
|
EP2444419A1
(en)
|
2005-04-26 |
2012-04-25 |
Pfizer Inc. |
P-Cadherin antibodies
|
JP2009500377A
(ja)
|
2005-07-08 |
2009-01-08 |
ノボ・ノルデイスク・エー/エス |
ジシクロアルキルウレア型グルコキナーゼ活性化剤
|
WO2007015578A1
(ja)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を検定する方法
|
PE20080035A1
(es)
|
2005-09-07 |
2008-01-30 |
Amgen Fremont Inc |
Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
|
DK1926996T3
(da)
|
2005-09-20 |
2012-01-23 |
Osi Pharmaceuticals Llc |
Biologiske markører, som er prædiktive for anti-cancer-reaktion på insulinlignende vækstfaktor-1-receptorkinasehæmmere
|
US20080108664A1
(en)
*
|
2005-12-23 |
2008-05-08 |
Liu Belle B |
Solid-state form of AMG 706 and pharmaceutical compositions thereof
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
ES2353482T3
(es)
*
|
2006-02-10 |
2011-03-02 |
Amgen, Inc |
Formas hidrato de amg706.
|
WO2007121269A2
(en)
|
2006-04-11 |
2007-10-25 |
Ardea Biosciences, Inc. |
N-aryl-n'alkyl sulfamides as mek inhibitors
|
EP2012786B1
(en)
*
|
2006-04-18 |
2010-10-06 |
Ardea Biosciences, Inc. |
Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
|
AU2007251282A1
(en)
|
2006-05-09 |
2007-11-22 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
RU2448708C3
(ru)
|
2006-05-18 |
2017-09-28 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое средство против рака щитовидной железы
|
WO2007143600A2
(en)
*
|
2006-06-05 |
2007-12-13 |
Incyte Corporation |
Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
|
PT2076502E
(pt)
*
|
2006-06-08 |
2011-06-07 |
Lilly Co Eli |
Carboxamidas substituídas
|
US7932390B2
(en)
|
2006-06-29 |
2011-04-26 |
Hoffman-La Roche Inc. |
Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
|
PE20080403A1
(es)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
KR101472600B1
(ko)
|
2006-08-28 |
2014-12-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암에 대한 항종양제
|
US7687522B2
(en)
|
2006-12-20 |
2010-03-30 |
Amgen Inc. |
Substituted pyridines and pyrimidines and their use in treatment of cancer
|
CA2673652A1
(en)
|
2007-01-09 |
2008-07-17 |
Amgen Inc. |
Bis-aryl amide derivatives and methods of use
|
WO2008093855A1
(ja)
|
2007-01-29 |
2008-08-07 |
Eisai R & D Management Co., Ltd. |
未分化型胃癌治療用組成物
|
MX2009008531A
(es)
|
2007-02-16 |
2009-08-26 |
Amgen Inc |
Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
|
KR20090115749A
(ko)
*
|
2007-02-26 |
2009-11-05 |
산텐 세이야꾸 가부시키가이샤 |
우레이드기와 아미노카르보닐기를 치환기로서 갖는 신규 피롤 유도체
|
EP2851091B1
(en)
|
2007-04-13 |
2017-12-27 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to ERBB therapeutics
|
US20100255004A1
(en)
*
|
2007-04-13 |
2010-10-07 |
Dana Farber Cancer Institute |
Receptor tyrosine kinase profiling
|
US8509487B2
(en)
*
|
2007-04-19 |
2013-08-13 |
Avago Technologies General Ip (Singapore) Pte. Ltd. |
System and method for optically measuring a parameter of an object
|
MX2010001636A
(es)
|
2007-08-14 |
2010-03-15 |
Hoffmann La Roche |
Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
|
NO2188313T3
(ko)
|
2007-08-21 |
2018-03-31 |
|
|
WO2009060945A1
(ja)
|
2007-11-09 |
2009-05-14 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質と抗腫瘍性白金錯体との併用
|
US20100029491A1
(en)
*
|
2008-07-11 |
2010-02-04 |
Maike Schmidt |
Methods and compositions for diagnostic use for tumor treatment
|
KR101596539B1
(ko)
|
2008-12-23 |
2016-02-22 |
제넨테크, 인크. |
암 환자에서의 진단 목적용 방법 및 조성물
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
WO2010099364A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
PE20120770A1
(es)
|
2009-03-25 |
2012-07-10 |
Genentech Inc |
ANTICUERPOS ANTI alfa5ß1 CON ACTIVIDAD SOBRE GLIOBLASTOMAS
|
US20110076271A1
(en)
|
2009-07-13 |
2011-03-31 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
EP2459191A1
(en)
|
2009-07-31 |
2012-06-06 |
OSI Pharmaceuticals, LLC |
Mtor inhibitor and angiogenesis inhibitor combination therapy
|
ES2530732T3
(es)
|
2009-09-17 |
2015-03-05 |
Hoffmann La Roche |
Procedimientos de diagnóstico para el cáncer de pulmón
|
WO2011073521A1
(en)
|
2009-12-15 |
2011-06-23 |
Petri Salven |
Methods for enriching adult-derived endothelial progenitor cells and uses thereof
|
CN102770158B
(zh)
|
2009-12-21 |
2016-10-19 |
霍夫曼-拉罗奇有限公司 |
抗体配制剂
|
HUE030969T2
(en)
|
2010-02-12 |
2017-06-28 |
Pfizer |
Salts and Polymorphs of 8-Fluoro-2- {4 - [(methylamino) methyl] phenyl} -1,3,4,5-tetrahydro-6H-azepino [5,4,3-CD] indol-6-one
|
US20110275644A1
(en)
|
2010-03-03 |
2011-11-10 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
EP2542893A2
(en)
|
2010-03-03 |
2013-01-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
EP3135692B8
(en)
|
2010-06-16 |
2019-03-20 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Antibodies to endoplasmin and their use
|
WO2011161217A2
(en)
|
2010-06-23 |
2011-12-29 |
Palacký University in Olomouc |
Targeting of vegfr2
|
BR112012032462A2
(pt)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
|
EP2596026B1
(en)
|
2010-07-23 |
2020-04-08 |
Trustees of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
UA112539C2
(uk)
|
2011-03-03 |
2016-09-26 |
Новартіс Аг |
Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
|
EP2937349B1
(en)
|
2011-03-23 |
2016-12-28 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
ES2671748T3
(es)
|
2011-07-21 |
2018-06-08 |
Tolero Pharmaceuticals, Inc. |
Inhibidores heterocíclicos de proteína quinasas
|
US9745288B2
(en)
|
2011-08-16 |
2017-08-29 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
ES2851602T3
(es)
|
2011-12-28 |
2021-09-08 |
Allergan Inc |
Derivados de 3-fenil-5-ureidoisotiazol-4-carboxamida como inhibidores de cinasa
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
CN103508961B
(zh)
|
2012-06-26 |
2015-07-22 |
中美冠科生物技术(太仓)有限公司 |
抗肿瘤药物
|
WO2014036022A1
(en)
|
2012-08-29 |
2014-03-06 |
Amgen Inc. |
Quinazolinone compounds and derivatives thereof
|
JP6243918B2
(ja)
|
2012-10-16 |
2017-12-06 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
Pkm2調節因子およびそれらの使用方法
|
CN104755463A
(zh)
|
2012-12-21 |
2015-07-01 |
卫材R&D管理有限公司 |
非晶态形式的喹啉衍生物及其生产方法
|
CA2906057A1
(en)
|
2013-03-13 |
2014-10-02 |
Genentech, Inc. |
Antibody formulations
|
DK2968650T3
(en)
|
2013-03-14 |
2019-03-11 |
Panoptica Inc |
EYE PHARMACEUTICAL FORMULATIONS FOR THE POSTERIOR EYE SEGMENT
|
RU2019119893A
(ru)
|
2013-03-14 |
2019-08-09 |
Толеро Фармасьютикалз, Инк. |
Ингибиторы jak2 и alk2 и способы их использования
|
MX368099B
(es)
|
2013-05-14 |
2019-09-19 |
Eisai R&D Man Co Ltd |
Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
|
CN106536753B
(zh)
|
2014-04-04 |
2020-07-21 |
中美冠科生物技术(太仓)有限公司 |
用于确定对mek/erk抑制剂的应答性的方法
|
KR102329681B1
(ko)
|
2014-08-28 |
2021-11-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
고순도의 퀴놀린 유도체 및 이를 제조하는 방법
|
WO2016044334A1
(en)
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Antibody formulations
|
EP3193867B1
(en)
|
2014-09-17 |
2021-01-20 |
PanOptica, Inc. |
Ocular formulations for drug-delivery and protection of the anterior segment of the eye
|
US9353093B2
(en)
|
2014-10-07 |
2016-05-31 |
Allergan, Inc. |
Indole-1-carboxamides as kinase inhibitors
|
US9403803B2
(en)
|
2014-10-08 |
2016-08-02 |
Allergan, Inc. |
Indole-3-carboxamides as kinase inhibitors
|
US9371314B2
(en)
|
2014-10-09 |
2016-06-21 |
Allergan, Inc. |
Pyridyl benzothiophenes as kinase inhibitors
|
US9359336B2
(en)
|
2014-10-09 |
2016-06-07 |
Allergan, Inc. |
Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
|
EP3233829B1
(en)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
US11083755B2
(en)
|
2015-01-08 |
2021-08-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Factors and cells that provide for induction of bone, bone marrow, and cartilage
|
BR112017017428A2
(pt)
|
2015-02-25 |
2018-04-03 |
Eisai R&D Management Co., Ltd. |
?método para supressão do amargor de derivado de quinolina?
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
RU2717829C2
(ru)
|
2015-04-20 |
2020-03-26 |
Толеро Фармасьютикалз, Инк. |
Прогнозирование ответа на альвоцидиб с помощью анализа профиля митохондрий
|
DK3298021T3
(da)
|
2015-05-18 |
2019-08-05 |
Tolero Pharmaceuticals Inc |
Alvocidib-prodrugs, der har øget biotilgængelighed
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
KR20180034538A
(ko)
|
2015-08-03 |
2018-04-04 |
톨레로 파마수티컬스, 인크. |
암의 치료를 위한 병행 요법
|
GB2543550A
(en)
|
2015-10-21 |
2017-04-26 |
Hox Therapeutics Ltd |
Peptides
|
CN108601752A
(zh)
|
2015-12-03 |
2018-09-28 |
安吉奥斯医药品有限公司 |
用于治疗mtap缺失型癌症的mat2a抑制剂
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
US10132797B2
(en)
|
2016-12-19 |
2018-11-20 |
Tolero Pharmaceuticals, Inc. |
Profiling peptides and methods for sensitivity profiling
|
UA124474C2
(uk)
|
2016-12-22 |
2021-09-22 |
Емджен Інк. |
БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
EP3679040B1
(en)
|
2017-09-08 |
2022-08-03 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
WO2019213526A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3788038B1
(en)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
AU2019265822B2
(en)
|
2018-05-10 |
2024-07-18 |
Amgen Inc. |
KRAS G12C inhibitors for the treatment of cancer
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
MA52780A
(fr)
|
2018-06-11 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
MX2020008905A
(es)
|
2018-06-12 |
2020-12-03 |
Vtv Therapeutics Llc |
Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
|
JP7369719B2
(ja)
|
2018-06-12 |
2023-10-26 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
AU2019310590A1
(en)
|
2018-07-26 |
2021-01-14 |
Sumitomo Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
MX2021005700A
(es)
|
2018-11-19 |
2021-07-07 |
Amgen Inc |
Inhibidores de kras g12c y metodos de uso de los mismos.
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
CA3119807A1
(en)
|
2018-12-04 |
2020-06-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
MA54543A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
MA54550A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
EP3898592A1
(en)
|
2018-12-20 |
2021-10-27 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
AU2020221247A1
(en)
|
2019-02-12 |
2021-08-05 |
Sumitomo Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
US20230148450A9
(en)
|
2019-03-01 |
2023-05-11 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
CN113727758A
(zh)
|
2019-03-01 |
2021-11-30 |
锐新医药公司 |
双环杂环基化合物及其用途
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
AU2020245437A1
(en)
|
2019-03-22 |
2021-09-30 |
Sumitomo Pharma Oncology, Inc. |
Compositions comprising PKM2 modulators and methods of treatment using the same
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
CA3140392A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
CA3146693A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CA3147276A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
MX2022001181A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
JP2022553858A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
CR20220240A
(es)
|
2019-11-04 |
2022-08-03 |
Revolution Medicines Inc |
Inhibidores de ras
|
MX2022005360A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
BR112022008858A2
(pt)
|
2019-11-08 |
2022-09-06 |
Revolution Medicines Inc |
Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
|
JP2023501528A
(ja)
|
2019-11-14 |
2023-01-18 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の改善された合成
|
TW202132271A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Kras g12c抑制劑化合物之改善的合成
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
KR20220124768A
(ko)
|
2020-01-07 |
2022-09-14 |
레볼루션 메디슨즈, 인크. |
Shp2 억제제 투여 및 암 치료방법
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
KR20230081726A
(ko)
|
2020-09-03 |
2023-06-07 |
레볼루션 메디슨즈, 인크. |
Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
|
JP2023541916A
(ja)
|
2020-09-15 |
2023-10-04 |
レボリューション メディシンズ インコーポレイテッド |
がんの治療における、ras阻害剤としてのインドール誘導体
|
CA3203111A1
(en)
|
2020-12-22 |
2022-06-30 |
Kailiang Wang |
Sos1 inhibitors and uses thereof
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
EP4334321A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Ras inhibitors
|
PE20240089A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cancer
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
WO2024140850A1
(zh)
*
|
2022-12-28 |
2024-07-04 |
苏州必扬医药科技有限公司 |
一种蛋白酪氨酸激酶抑制剂及其医药用途
|